Grants per year
Personal profile
Research Interests
The elucidation of eukaryotic signal transduction pathways, the study of signal transduction pathway perturbation in disease or injury, and the utilization of this knowledgebase for rational drug discovery and development.
Training Experience
| 1977 | Postdoctoral Fellowship, Duke University |
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
PhD, Biochemistry/Chemistry, Emory University
… → 1975
Research interests keywords
- Alzheimer's Drug
- Biochemistry: Proteins
- Brain Cancer / Nervous System Cancer
- Brain Injury
- Drug Discovery
- Neuroinflammation
- Pharmacology
- Signal Transduction
Fingerprint
Dive into the research topics where Daniel M Watterson is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
GMP Production and Extended Toxicology of an Oral Formulation Drug for Alzheimer's Disease
Watterson, D. M. (PD/PI) & Watterson, D. M. (PD/PI)
6/1/22 → 5/31/26
Project: Research project
-
CardioExcyte 96 System for Pharmacology Research at Northwestern University
George, A. L. (PD/PI), Abdulkadir, S. A. (Other), Ardehali, H. (Other), Arora, R. K. (Other), Burridge, P. (Other), Kearney, J. A. (Other), McNally, E. M. (Other), Schiltz, G. E. (Other), Silverman, R. B. (Other), Watterson, D. M. (Other) & Wilsbacher, L. D. (Other)
Office of the Director, National Institutes of Health
6/15/20 → 6/30/25
Project: Research project
-
Preclinical development of a novel small molecule inhibitor of Alzheimer's disease-related cognitive impairment
Watterson, D. M. (PD/PI), Watterson, D. M. (PD/PI), Watterson, D. M. (PD/PI), Anderson, W. F. (Co-Investigator) & Anderson, W. F. (Co-Investigator)
5/15/20 → 4/30/25
Project: Research project
-
Production and quality analysis of clinical drug for a novel CNS protein kinase inhibitor therapeutic candidate
Watterson, D. M. (PD/PI)
NeuroKine Therapeutics, LLC, National Institute on Aging
5/15/19 → 4/30/21
Project: Research project
-
Phase 1 studies of MW151, a selective small molecule suppressor of neuroinflammation for Alzheimer’s disease
Watterson, D. M. (PD/PI)
University of Kentucky, Alzheimer's Drug Discovery Foundation
4/1/19 → 9/30/21
Project: Research project
-
The 5HT2b Receptor in Alzheimer's Disease: Increased Levels in Patient Brains and Antagonist Attenuation of Amyloid and Tau Induced Dysfunction
Acquarone, E., Argyrousi, E. K., Arancio, O., Watterson, D. M. & Roy, S. M., Apr 16 2024, In: Journal of Alzheimer's Disease. 98, 4, p. 1349-1360 12 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
PI3Kγ stimulates a high molecular weight form of myosin light chain kinase to promote myeloid cell adhesion and tumor inflammation
Schmid, M. C., Kang, S. W., Chen, H., Paradise, M., Ghebremedhin, A., Kaneda, M. M., Chin, S. M., Do, A., Watterson, D. M. & Varner, J. A., Dec 2022, In: Nature communications. 13, 1, 1768.Research output: Contribution to journal › Article › peer-review
Open Access8 Scopus citations -
Therapeutic treatment with the antiinflammatory drug candidate MW151 may partially reduce memory impairment and normalizes hippocampal metabolic markers in a mouse model of comorbid amyloid and vascular pathology
Braun, D. J., Powell, D. K., McLouth, C. J., Roy, S. M., Watterson, D. M. & Van Eldik, L. J., Jan 2022, In: PloS one. 17, 1 January, e0262474.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
First-in-Human Studies of MW01-6-189WH, a Brain-Penetrant, Antineuroinflammatory Small-Molecule Drug Candidate: Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Studies in Healthy Adult Volunteers
Van Eldik, L. J., Sawaki, L., Bowen, K., Laskowitz, D. T., Noveck, R. J., Hauser, B., Jordan, L., Spears, T. G., Wu, H., Watt, K., Raja, S., Roy, S. M., Watterson, D. M. & Guptill, J. T., Feb 2021, In: Clinical Pharmacology in Drug Development. 10, 2, p. 131-143 13 p.Research output: Contribution to journal › Article › peer-review
Open Access7 Scopus citations -
Phosphorylation-dependent subcellular redistribution of small myosin light chain kinase
Khapchaev, A. Y., Watterson, D. M. & Shirinsky, V. P., Oct 2021, In: Biochimica et Biophysica Acta - Molecular Cell Research. 1868, 11, 119104.Research output: Contribution to journal › Article › peer-review
Open Access
Datasets
-
3EH9 : Crystal structure of death associated protein kinase complexed with ADP
McNamara, L. K. (Contributor), Brunzelle, J. S. (Contributor) & Watterson, D. M. (Contributor), RCSB-PDB, 2009
DOI: 10.2210/pdb3eh9/pdb, https://www.rcsb.org/structure/3EH9
Dataset
-
4R3C : Crystal structure of p38 alpha MAP kinase in complex with a novel isoform selective drug candidate
Roy, S. M. (Contributor), Grum-Tokars, V. L. (Contributor), Minasov, G. (Contributor), Anderson, W. F. (Contributor) & Watterson, D. M. (Contributor), RCSB-PDB, 2015
DOI: 10.2210/pdb4r3c/pdb, https://www.rcsb.org/structure/4R3C
Dataset
-
Additional file 2: Table S2. of Retention of normal glia function by an isoform-selective protein kinase inhibitor drug candidate that modulates cytokine production and cognitive outcomes
Zhou, Z. (Contributor), Bachstetter, A. D. (Creator), Späni, C. B. (Creator), Roy, S. M. (Contributor), Watterson, D. M. (Contributor) & Van Eldik, L. J. (Contributor), figshare, 2017
DOI: 10.6084/m9.figshare.c.3735430_d2.v1, https://springernature.figshare.com/articles/dataset/Additional_file_2_Table_S2_of_Retention_of_normal_glia_function_by_an_isoform-selective_protein_kinase_inhibitor_drug_candidate_that_modulates_cytokine_production_and_cognitive_outcomes/4822510/1
Dataset
-
Additional file 3: Table S3. of Retention of normal glia function by an isoform-selective protein kinase inhibitor drug candidate that modulates cytokine production and cognitive outcomes
Zhou, Z. (Contributor), Bachstetter, A. D. (Creator), Späni, C. B. (Creator), Roy, S. M. (Contributor), Watterson, D. M. (Contributor) & Van Eldik, L. J. (Contributor), figshare, 2017
DOI: 10.6084/m9.figshare.c.3735430_d3.v1, https://springernature.figshare.com/articles/dataset/Additional_file_3_Table_S3_of_Retention_of_normal_glia_function_by_an_isoform-selective_protein_kinase_inhibitor_drug_candidate_that_modulates_cytokine_production_and_cognitive_outcomes/4822528/1
Dataset
-
3F5G : Crystal structure of death associated protein kinase in complex with ADP and Mg2+
McNamara, L. K. (Contributor), Brunzelle, J. S. (Contributor) & Watterson, D. M. (Contributor), RCSB-PDB, 2009
DOI: 10.2210/pdb3f5g/pdb, https://www.rcsb.org/structure/3F5G
Dataset